Provided below are an analyst's forecasts of revenue, net operating profit after tax (NOPAT), and net operating assets (NOA) as of 12/31/2020 for Abbott Laboratories. The following additional information is provided (dollar and share amounts in millions). Common shares outstanding: 1,771.230 Net nonoperating obligations (NNO): \$11,576.0 Noncontrolling interest ( NCl ): $219.0 Preferred stock: $0.0 WACC: 4.0% Terminal growth: 2.0% Use the discounted cash flow (DCF) method to answer the following questions. Do not round intermediate calculations. All values other than per-share amounts are shown in millions